Moclobemide
Severe
Textbook
Increased risk of adverse cardiovascular effects.
At least 2 weeks should elapse between the use of MAO inhibitors and administration of β2 agonists or other sympathomimetics.
Source: G&G 14e · p264
Drug reference
Olodaterol
LABA · Agent for Obstructive Airway Diseases
Also known as Olodaterol hydrochloride
LABAAgent for Obstructive Airway DiseasesATC R03AC19
CDSCO approvedSchedule HATC R03AC19
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- MoclobemideSevereTextbookG&G 14e · p264
- CarteololSevereDatabaseDDInter
- CarvedilolSevereDatabaseDDInter
- LabetalolSevereDatabaseDDInter
Mechanism
Olodaterol is an ultralong-acting beta-2 selective adrenergic agonist. It acts by stimulating beta-2 receptors in the bronchial smooth muscle. This stimulation leads to bronchodilation, thereby helping to improve airflow in patients with chronic obstructive pulmonary disease.
Indications
Maintenance treatment of chronic obstructive pulmonary diseaseCOPD
Dosing
- Adult
- 5 micrograms once daily by inhalation, as part of a fixed-dose combination product (equivalent to 2 puffs of inhalation solution).
- Max dose
- 5 micrograms once daily
Pharmacokinetics
Duration
Supports once-daily dosing
Side effects
Common
Muscle tremorTachycardiaPalpitations
Serious
- Hypokalemia
- Ventilation-perfusion (V/Q) mismatch (fall in arterial oxygen tension)
- Metabolic effects (increase in free fatty acid, insulin, glucose, pyruvate, and lactate)
- Life-threatening and fatal asthma exacerbations (if used alone in asthma)
Drug interactions
Carteolol
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Carvedilol
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Labetalol
Severe
Database
Clinical effect not specified
Source: DDInter
Levobunolol
Severe
Database
Clinical effect not specified
Source: DDInter
Macimorelin
Severe
Database
Clinical effect not specified
Source: DDInter
Metipranolol
Severe
Database
Clinical effect not specified
Source: DDInter
Nadolol
Severe
Database
Clinical effect not specified
Source: DDInter
Ozanimod
Severe
Database
Clinical effect not specified
Source: DDInter
Penbutolol
Severe
Database
Clinical effect not specified
Source: DDInter
Pindolol
Severe
Database
Clinical effect not specified
Source: DDInter
Propranolol
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other LABA drugs
Ask House about Olodaterol
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team